These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
570 related articles for article (PubMed ID: 25750267)
1. Role of inflammatory infiltrates in triple negative breast cancer. Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267 [TBL] [Abstract][Full Text] [Related]
2. Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer. Matsumoto H; Thike AA; Li H; Yeong J; Koo SL; Dent RA; Tan PH; Iqbal J Breast Cancer Res Treat; 2016 Apr; 156(2):237-47. PubMed ID: 26960711 [TBL] [Abstract][Full Text] [Related]
3. Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes. Lee HJ; Lee JJ; Song IH; Park IA; Kang J; Yu JH; Ahn JH; Gong G Breast Cancer Res Treat; 2015 Jun; 151(3):619-27. PubMed ID: 26006068 [TBL] [Abstract][Full Text] [Related]
4. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer. Kim YA; Lee HJ; Heo SH; Park HS; Park SY; Bang W; Song IH; Park IA; Gong G Breast Cancer Res Treat; 2016 Apr; 156(3):597-606. PubMed ID: 27075916 [TBL] [Abstract][Full Text] [Related]
5. The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Wang K; Shen T; Siegal GP; Wei S Hum Pathol; 2017 Nov; 69():110-117. PubMed ID: 28993275 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974 [TBL] [Abstract][Full Text] [Related]
7. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach. Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482 [TBL] [Abstract][Full Text] [Related]
8. Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents. Santoni M; Romagnoli E; Saladino T; Foghini L; Guarino S; Capponi M; Giannini M; Cognigni PD; Ferrara G; Battelli N Biochim Biophys Acta Rev Cancer; 2018 Jan; 1869(1):78-84. PubMed ID: 29126881 [TBL] [Abstract][Full Text] [Related]
9. The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis. Ibrahim EM; Al-Foheidi ME; Al-Mansour MM; Kazkaz GA Breast Cancer Res Treat; 2014 Dec; 148(3):467-76. PubMed ID: 25361613 [TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. Zhang C; Han Y; Huang H; Min L; Qu L; Shou C Int J Oncol; 2014 Jun; 44(6):2025-33. PubMed ID: 24676531 [TBL] [Abstract][Full Text] [Related]
11. Landscape of toll-like receptors expression in tumor microenvironment of triple negative breast cancer (TNBC): Distinct roles of TLR4 and TLR8. Roychowdhury A; Jondhale M; Saldanha E; Ghosh D; Kumar Panda C; Chandrani P; Mukherjee N Gene; 2021 Aug; 792():145728. PubMed ID: 34022297 [TBL] [Abstract][Full Text] [Related]
12. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer. Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617 [TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy. Miyashita M; Sasano H; Tamaki K; Chan M; Hirakawa H; Suzuki A; Tada H; Watanabe G; Nemoto N; Nakagawa S; Ishida T; Ohuchi N Breast Cancer Res Treat; 2014 Dec; 148(3):525-34. PubMed ID: 25395319 [TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structures and associated plasma cells play an important role in the biology of triple-negative breast cancers. Seow DYB; Yeong JPS; Lim JX; Chia N; Lim JCT; Ong CCH; Tan PH; Iqbal J Breast Cancer Res Treat; 2020 Apr; 180(2):369-377. PubMed ID: 32034580 [TBL] [Abstract][Full Text] [Related]
15. Tumor-infiltrating lymphocytes and CD8 Vihervuori H; Autere TA; Repo H; Kurki S; Kallio L; Lintunen MM; Talvinen K; Kronqvist P J Cancer Res Clin Oncol; 2019 Dec; 145(12):3105-3114. PubMed ID: 31562550 [TBL] [Abstract][Full Text] [Related]
17. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661 [TBL] [Abstract][Full Text] [Related]
18. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels tumour heterogeneity plus M2-like tumour-associated macrophage infiltration and aggressiveness in TNBC. Bao X; Shi R; Zhao T; Wang Y; Anastasov N; Rosemann M; Fang W Cancer Immunol Immunother; 2021 Jan; 70(1):189-202. PubMed ID: 32681241 [TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer. Lee HJ; Park IA; Song IH; Shin SJ; Kim JY; Yu JH; Gong G J Clin Pathol; 2016 May; 69(5):422-30. PubMed ID: 26475777 [TBL] [Abstract][Full Text] [Related]
20. Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. Quintana Á; Peg V; Prat A; Moliné T; Villacampa G; Paré L; Galván P; Dientsmann R; Schmid P; Curigliano G; Muñoz-Couselo E; Perez-García J; Marti M; Blanco-Heredia J; Anjos CD; Vazquez M; De Mattos-Arruda L; Cortés J Eur J Cancer; 2021 May; 148():134-145. PubMed ID: 33743482 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]